within Pharmacolibrary.Drugs.ATC.R;

model R01AA06
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.4,
    Cl             = 0.02 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 0.5 / 1000000,
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tetryzoline (also known as tetrahydrozoline) is an imidazoline derivative used as a topical decongestant for relieving redness in the eyes and nasal congestion. It acts as an alpha-adrenergic agonist, causing vasoconstriction. Tetryzoline is available in over-the-counter ocular (eye drops) and nasal preparations in many countries but systemic/injectable use is not approved.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetics for healthy adult population based on published data for topical imidazoline decongestants and tetrahydrozoline class due to lack of primary PK studies on tetryzoline.</p><h4>References</h4><ol><li><p>Okur, NÜ, et al., &amp; Okur, ME (2020). In vitro-in vivo evaluation of tetrahydrozoline-loaded ocular in situ gels on rabbits for allergic conjunctivitis management. <i>Drug development research</i> 81(6) 716–727. DOI:<a href=&quot;https://doi.org/10.1002/ddr.21677&quot;>10.1002/ddr.21677</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/32359095/&quot;>https://pubmed.ncbi.nlm.nih.gov/32359095</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end R01AA06;
